Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Part 1 of the study will assess the enhancement of task-related brain activation (BOLD
response) in key brain areas in schizophrenia during the performance of working memory,
episodic memory and visual activation tasks as measured by functional magnetic resonance
imaging (fMRI) in people with schizophrenia. Part 2 of the study will assess the safety and
tolerability of multiple doses of AQW051 in people with schizophrenia.